Evidence supporting the use of: Bifidobacterium infantis
For the health condition: Autoimmune Disorders

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium infantis is a probiotic bacterium that has been studied for its potential to modulate the immune system and improve gut health. The rationale for its use in autoimmune disorders primarily stems from its ability to influence the gut microbiota and the gut-associated immune system, which are increasingly implicated in the pathogenesis of various autoimmune diseases. Scientific evidence suggests that certain strains of B. infantis can enhance the integrity of the intestinal barrier, reduce systemic inflammation, and promote the production of anti-inflammatory cytokines such as IL-10. Some small clinical trials and animal studies have shown benefits in conditions like inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, where B. infantis supplementation has led to modest improvements in symptoms and markers of inflammation. However, rigorous, large-scale clinical trials are still lacking, and results have sometimes been inconsistent or strain-specific. There is little direct evidence for its efficacy in other autoimmune conditions such as rheumatoid arthritis, type 1 diabetes, or multiple sclerosis. Overall, while the mechanistic basis and some preliminary clinical data support the potential for B. infantis in autoimmune disorders affecting the gut, the strength of the evidence is currently modest, and probiotic use should be considered as adjunctive rather than primary therapy pending further research.

More about Bifidobacterium infantis
More about Autoimmune Disorders